The Q3 earnings season has delivered several big winners, with Hasbro (HAS), IDEXX Laboratories (IDXX), and TG Therapeutics (TGTX) all posting strong results that have helped drive relative strength over the last month, with each raising also guidance in one way or another.
Eurizon Capital SGR S.p.A. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 7.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,201 shares of the company's stock after selling 2,090 shares during the period. Eurizon Capital SGR S.p.A.'s holdings
Allspring Global Investments Holdings LLC decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 3.7% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,241 shares of the company's stock after selling 1,583 shares during the quarter.
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Michael Lane sold 3,979 shares of the business's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $688.64, for a total transaction of $2,740,098.56. Following the sale, the executive vice president directly owned 4,076 shares of the company's
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Sharon Underberg sold 8,906 shares of the firm's stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total value of $6,132,582.54. Following the completion of the transaction, the executive vice president directly owned 7,169 shares
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IDEXX Laboratories continues to demonstrate robust growth, with Q3/26 results prompting an upward revision of FY26 revenue guidance to 10.1%-10.8%. VetLab consumables and CAG department revenues grew 16.1% and 11.3% respectively in the first nine months, underscoring core business strength. IDXX maintains pricing power, consistently passing on price increases and offsetting inflation, as evidenced by improved gross and operating margins.
IDEXX Laboratories delivered strong Q3 results, beating expectations with 9.86% organic revenue growth and raising full-year revenue and EPS guidance. I maintain my buy rating on IDXX, citing its best-in-class diagnostics, high recurring revenue, and robust innovation pipeline supporting premium valuation. CoVet acquisition adds high-margin, AI-driven workflow software, enhancing stickiness and cross-selling, with a calculated purchase price near $223 million and double-digit growth potential.
From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Retirement savers who never chose IDEXX Laboratories (NASDAQ:IDXX | IDXX Price Prediction) got a lift from it anyway on Monday. The veterinary diagnostics company was up 20.2% in the regular session as of 1:54 PM ET, trading at $662.